首页> 外文期刊>临床与转化肝病杂志(英文版) >Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma
【24h】

Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma

机译:基于生物标志物的肝细胞癌MicroRNA治疗策略

获取原文
获取原文并翻译 | 示例
       

摘要

Recently, microRNAs (miRNAs) have emerged as key factors involved in a series of biological processes, ranging from embryogenesis to programmed cell death. Its link to aberrant expression profiles has rendered it a potentially attractive tool for the diagnosis, prognosis, or treatment of various diseases. Accumulating evidence has indicated that miRNAs act as tumor suppressors in hepatocyte malignant transformation by regulating development, differentiation, proliferation, and tumorigenesis. Here, we summarize recent progress in the development of novel biomarker-based miRNA therapeutic strategies for hepatocellular carcinoma (HCC).
机译:最近,microRNA(miRNA)已成为涉及一系列生物学过程(从胚胎发生到程序性细胞死亡)的关键因素。它与异常表达谱的联系使其成为诊断,预后或治疗各种疾病的潜在有吸引力的工具。越来越多的证据表明,miRNA通过调节发育,分化,增殖和肿瘤发生而在肝细胞恶性转化中起着抑癌作用。在这里,我们总结了肝细胞癌(HCC)新型基于生物标志物的miRNA治疗策略的发展中的最新进展。

著录项

  • 来源
    《临床与转化肝病杂志(英文版)》 |2014年第4期|253-258|共6页
  • 作者单位

    Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China;

    Department of Immunology, Medical School of Nantong University, Nantong, Jiangsu, China;

    Department of Medical Informatics, Medical School of Nantong University, Nantong, Jiangsu, China;

    The Hospital of Nantong Maternal and Child Care Service, Nantong, Jiangsu, China;

    The Hospital of Nantong Maternal and Child Care Service, Nantong, Jiangsu, China;

    Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:45:58
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号